SMT201400120B - Biological materials and their uses - Google Patents

Biological materials and their uses

Info

Publication number: SMT201400120B
Authority: SM; San Marino
Prior art keywords: biological materials; biological; materials
Prior art date: 2009-03-13

Application number

SM201400120T

Other languages

Italian (it)

Inventor

Kim Suzanne Midwood

Brian Maurice John Foxwell

Original Assignee

Imp Innovations Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-03-13

Filing date

2014-09-01

Publication date

2014-11-10

2014-09-01 Application filed by Imp Innovations Ltd filed Critical Imp Innovations Ltd

2014-11-10 Publication of SMT201400120B publication Critical patent/SMT201400120B/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Toxicology (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Hematology (AREA)
Pulmonology (AREA)
Rehabilitation Therapy (AREA)
Dermatology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Pain & Pain Management (AREA)
Neurosurgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Biomedical Technology (AREA)

SM201400120T 2009-03-13 2014-09-01 Biological materials and their uses SMT201400120B (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0904355.5A GB0904355D0 (en)	2009-03-13	2009-03-13	Biological materials and uses thereof
PCT/GB2010/000460 WO2010103289A1 (en)	2009-03-13	2010-03-15	Biological materials and uses thereof

Publications (1)

Publication Number	Publication Date
SMT201400120B true SMT201400120B (en)	2014-11-10

Family

ID=40637300

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SM201400120T SMT201400120B (en)	2009-03-13	2014-09-01	Biological materials and their uses

Country Status (18)

Country	Link
US (1)	US20130045212A1 (en)
EP (3)	EP2754668B1 (en)
JP (1)	JP5847590B2 (en)
CN (1)	CN102712686B (en)
AU (2)	AU2010222708B2 (en)
BR (1)	BRPI1009819A2 (en)
CA (1)	CA2754945C (en)
CY (1)	CY1115463T1 (en)
DK (1)	DK2406280T3 (en)
ES (1)	ES2491617T3 (en)
GB (1)	GB0904355D0 (en)
HK (1)	HK1199888A1 (en)
HR (1)	HRP20140710T1 (en)
PL (1)	PL2406280T3 (en)
PT (1)	PT2406280E (en)
SI (1)	SI2406280T1 (en)
SM (1)	SMT201400120B (en)
WO (1)	WO2010103289A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20180022792A9 (en) *	2009-03-13	2018-01-25	Karen Foxwell	Biological Materials and Uses Thereof
CA2894746A1 (en) *	2011-12-12	2013-06-20	Isis Innovation Limited	Biomarker and use thereof
WO2013169382A1 (en) *	2012-05-07	2013-11-14	DePuy Synthes Products, LLC	Methods and devices for treating intervertebral disc disease
WO2015104564A2 (en) *	2014-01-13	2015-07-16	Imperial Innovations Limited	Biological materials and therapeutic uses thereof
GB201414021D0 (en) *	2014-08-07	2014-09-24	Nascient Ltd	Biological materials and uses thereof
GB201517184D0 (en) *	2015-09-29	2016-02-10	Imp Innovations Ltd	Biological materials and uses thereof
GB201602414D0 (en) *	2016-02-10	2016-03-23	Nascient Ltd	Biological materials and uses thereof
GB201616596D0 (en) *	2016-09-29	2016-11-16	Nascient Limited	Epitope and antibodies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
GB9122820D0 (en) *	1991-10-28	1991-12-11	Wellcome Found	Stabilised antibodies
SE9400088D0 (en)	1994-01-14	1994-01-14	Kabi Pharmacia Ab	Bacterial receptor structures
US6124260A (en) *	1998-09-30	2000-09-26	Cedars-Sinai Medical Center	Inhibition of smooth muscle cell migration by Tenascin-C peptides
JP3646159B2 (en) *	2001-02-08	2005-05-11	国立大学法人三重大学	Anti-tenascin-C monoclonal antibody and hybridoma producing the antibody
AU2003258134A1 (en) *	2002-08-09	2004-02-25	Applera Corporation	Lung cancer target proteins and use thereof
JP2004217546A (en) *	2003-01-10	2004-08-05	Japan Science & Technology Agency	Labeled anti-tenascin-c monoclonal antibody
WO2005009366A2 (en) *	2003-07-24	2005-02-03	Cornell Research Foundation, Inc.	Restoring vascular function
WO2008154008A1 (en) *	2007-06-11	2008-12-18	The Scripps Research Institute	Methods and compositions for inhibiting toll-like receptor mediated immune responses

2009
- 2009-03-13 GB GBGB0904355.5A patent/GB0904355D0/en not_active Ceased
2010
- 2010-03-15 SI SI201030696T patent/SI2406280T1/en unknown
- 2010-03-15 PL PL10722160T patent/PL2406280T3/en unknown
- 2010-03-15 DK DK10722160.8T patent/DK2406280T3/en active
- 2010-03-15 BR BRPI1009819A patent/BRPI1009819A2/en not_active Application Discontinuation
- 2010-03-15 EP EP14162944.4A patent/EP2754668B1/en not_active Not-in-force
- 2010-03-15 EP EP10722160.8A patent/EP2406280B1/en not_active Not-in-force
- 2010-03-15 EP EP18170211.9A patent/EP3392269B1/en not_active Not-in-force
- 2010-03-15 AU AU2010222708A patent/AU2010222708B2/en not_active Ceased
- 2010-03-15 US US13/256,036 patent/US20130045212A1/en not_active Abandoned
- 2010-03-15 WO PCT/GB2010/000460 patent/WO2010103289A1/en active Application Filing
- 2010-03-15 PT PT107221608T patent/PT2406280E/en unknown
- 2010-03-15 ES ES10722160.8T patent/ES2491617T3/en active Active
- 2010-03-15 CN CN201080021111.0A patent/CN102712686B/en not_active Expired - Fee Related
- 2010-03-15 CA CA2754945A patent/CA2754945C/en not_active Expired - Fee Related
- 2010-03-15 JP JP2011553518A patent/JP5847590B2/en not_active Expired - Fee Related
2014
- 2014-07-23 HR HRP20140710AT patent/HRP20140710T1/en unknown
- 2014-08-08 CY CY20141100640T patent/CY1115463T1/en unknown
- 2014-08-13 AU AU2014213514A patent/AU2014213514B2/en not_active Ceased
- 2014-09-01 SM SM201400120T patent/SMT201400120B/en unknown
2015
- 2015-01-13 HK HK15100337.5A patent/HK1199888A1/en unknown

Also Published As

Publication number	Publication date
WO2010103289A1 (en)	2010-09-16
SI2406280T1 (en)	2014-09-30
EP3392269A1 (en)	2018-10-24
JP5847590B2 (en)	2016-01-27
EP3392269B1 (en)	2021-10-27
HK1199888A1 (en)	2015-07-24
CA2754945C (en)	2020-03-10
US20130045212A1 (en)	2013-02-21
CN102712686A (en)	2012-10-03
AU2014213514B2 (en)	2016-07-14
DK2406280T3 (en)	2014-07-28
AU2010222708A1 (en)	2011-10-06
EP2754668A3 (en)	2014-07-30
EP2406280B1 (en)	2014-05-14
CN102712686B (en)	2017-10-17
BRPI1009819A2 (en)	2016-11-16
CY1115463T1 (en)	2017-01-04
GB0904355D0 (en)	2009-04-29
EP2754668B1 (en)	2018-05-09
HRP20140710T1 (en)	2014-09-26
AU2014213514A1 (en)	2014-09-04
AU2010222708B2 (en)	2014-07-24
ES2491617T3 (en)	2014-09-08
EP2406280A1 (en)	2012-01-18
JP2012520278A (en)	2012-09-06
PT2406280E (en)	2014-08-28
PL2406280T3 (en)	2014-11-28
CA2754945A1 (en)	2010-09-16
EP2754668A2 (en)	2014-07-16

Publication	Publication Date	Title
NO2023015I1 (en)	2023-04-11	Benzovindiflupyr and Difenoconazole
NL350111I2 (en)	2024-01-10	fenpicoxamid and prothioconazole
SMT201600335B (en)	2016-11-10	PROTEINS BINDING HETERODIMERS AND THEIR USES
SMT201600098B (en)	2016-04-29	ANTAGONISTS OF COMPLEMENT AND THEIR USES
BRPI1008947A2 (en)	2016-08-16	new materials
SMT201400120B (en)	2014-11-10	Biological materials and their uses
BRPI1012533A2 (en)	2015-09-22	pyradazinone compound and use thereof
SMT201600261B (en)	2016-11-10	OLIGOPEPTIDIC COMPOUNDS AND THEIR USES
SMAP201000115A (en)	2011-01-19	New heterocyclic compounds and their uses.
DK2252395T3 (en)	2021-08-09	SULFURSULATION MATERIALS
BRPI0907231A2 (en)	2019-09-24	pyrrolpyrimidines and pyrrolpyridines
BR112012011724A2 (en)	2018-03-27	porous materials
BRPI1011694A2 (en)	2016-10-25	category similators
BRPI1004349A2 (en)	2018-02-06	label set and usage
BRPI1007494A2 (en)	2016-02-16	compound and use thereof
SMT201500218B (en)	2015-10-30	Aryl-phenylsulfonamido-cycloalkyl compounds and their use
GB0904825D0 (en)	2009-05-06	Biological materials and uses thereof
SMT201500273B (en)	2016-01-08	DIHYROETHORPHINS AND THEIR PREPARATION
BRPI0921487A2 (en)	2016-01-19	conical crusher
DK2382224T3 (en)	2014-08-25	Metalhydracid materials
BRPI1011982A2 (en)	2015-09-22	combinations of flubendiamides and useful organisms.
SMT201600217B (en)	2016-08-31	FURANCARBOSSAMIDS SUBSTITUTED AND THEIR USE
FR2950073B1 (en)	2013-10-11	MICRO-PLATE
ES1071902Y (en)	2010-07-22	THERMOSOLDING AND PRECORT MECHANISM
FR2947248B1 (en)	2011-08-19	PALETTE